Good evening :)
Sai Life Sciences Limited

Sai Life Sciences Limited

SAILIFE Share Price

NSE
₹1,542.300.98% (-15.20)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max
SIP

With a market cap of ₹33,092 cr, stock is ranked 260

Stock is 2.46x as volatile as Nifty

SAILIFE Stock Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Avg

Financials growth has been moderate for a few years

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

With a market cap of ₹33,092 cr, stock is ranked 260

Stock is 2.46x as volatile as Nifty

SAILIFE Performance & Key Metrics

SAILIFE Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
91.4913.32—
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
45.815.760.50%

SAILIFE Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 
88%
Analysts have suggested that investors can buy this stock

from 8 analysts

Price Upside

Earnings Growth

Rev. Growth

See Detailed Forecast

SAILIFE Company Profile

Sai Life Sciences Limited is a contract research, development, and manufacturing organization (CRO/CDMO) providing tailored services for pharmaceutical and biotechnology industries, from drug discovery to commercial launch.

Investor Presentation

View older View older 

Aug 7, 2026

PDF
View Older Presentations

SAILIFE Similar Stocks (Peers)

Compare with peers Compare with peers 

SAILIFE Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
148.41
148.41
1Y Return
6.54%
6.54%
Buy Reco %
69.23
69.23
PE Ratio
78.92
78.92
1Y Return
18.05%
18.05%
Buy Reco %
100.00
100.00
PE Ratio
92.01
92.01
1Y Return
114.21%
114.21%
Buy Reco %
87.50
87.50
PE Ratio
-242.83
-242.83
1Y Return
16.98%
16.98%
Buy Reco %
100.00
100.00
PE Ratio
72.88
72.88
1Y Return
11.55%
11.55%
Buy Reco %
100.00
100.00
Compare with Peers

SAILIFE Sentiment Analysis

SAILIFE Sentiment Analysis

New
Crisp summary & key insights to decode earnings calls instantly

SAILIFE Stock Summary · May 2026

Management framed the quarter as a validation of its integrated CRDMO strategy, reporting revenue growth of 29% year‑on‑year and announcing a stepped‑up FY27 capex program of INR 1,100–1,300 crore to support the next phase of expansion. They highlighted broad‑based growth across CRO and CDMO, deeper multi‑service engagements with large pharma clients and a growing late‑stage pipeline, while stressing priorities on capacity buildouts, automation, DMPK/biology scale, ADC and peptide capability development and targeted AI/digital investments to lift productivity. Management struck a confident but measured tone, noting stronger CDMO visibility and several recently commercialized products expected to contribute in FY27, yet acknowledging tensions: customer concentration and supply‑chain cost pressures, short‑term inefficiencies and margin volatility as new plants commission, and limited visibility on exact commercialization timing. Looking ahead, they said capex will be phased to customer demand, leverage will remain healthy, CDMO growth is expected to continue and they anticipate FY27 second‑half strength as new capacity and investments come online.

SAILIFE Stock Growth Drivers
SAILIFE Stock Growth Drivers
7
  • Robust FY26 financial performance and improved profitability

    The company delivered materially stronger FY26 results with revenue up 29%, EBITDA up 56% and

  • Integrated CRDMO platform and deepening large‑pharma relationships

    The company’s integrated discovery‑to‑commercial CRDMO model is a structural differentiator that is increasing its relevance

SAILIFE Stock Challenges
SAILIFE Stock Challenges
5
  • Geopolitical-driven input and logistics cost pressure

    Ongoing geopolitical tensions, including developments in the Middle East, have increased input costs and disrupted

  • Capex-driven near-term financial strain and efficiency drag

    A sizable expansion program is elevating costs and creating funding and efficiency risks: the firm

SAILIFE Forecast

SAILIFE Forecasts

Price

Revenue

Earnings

SAILIFE

SAILIFE

Income

Balance Sheet

Cash Flow

SAILIFE Income Statement

SAILIFE Income Statement

Loading...

Quartermar 2024jun 2024sep 2024dec 2024mar 2025jun 2025sep 2025dec 2025mar 2026jun 2026
Total Revenue442.55287.84405.52448.89589.11506.32552.80564.84617.95557.83
Operating & Other expensessubtract314.55253.61293.34320.03421.93375.49391.65376.90425.59406.28
Depreciation/Amortizationsubtract31.0531.0735.9234.0937.4937.7239.7544.0845.3145.94
Interest & Other Itemssubtract20.8921.2220.9323.1310.8912.369.359.707.837.64
Taxes & Other Itemssubtract19.92-4.5713.8217.8030.5320.3028.2033.8034.9924.69
EPS31.00-0.742.222.894.242.904.014.774.933.46

SAILIFE Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2027FY 2027

Annual Report Pending

Investor Presentation

Aug 7PDF
FY 2026FY 2026

Annual report

PDF

Investor Presentation

May 15PDF
Feb 6PDF
Nov 7PDF
Aug 8PDF
FY 2025FY 2025

Annual report

PDF

Investor Presentation

May 14PDF
Feb 25PDF
Feb 7PDF
 

SAILIFE Stock Peers

SAILIFE Past Performance & Peer Comparison

SAILIFE Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CareBiotechnology

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Sai Life Sciences Limited94.8513.32—
Biocon Limited148.411.560.14%
Anthem Biosciences Limited78.9215.350.24%
Acutaas Chemicals Ltd92.0119.160.06%
ScreenerCompare valuation on Screener

SAILIFE Stock Price Comparison

Compare SAILIFE with any stock or ETF
Compare SAILIFE with any stock or ETF
SAILIFE
Loading...

SAILIFE Holdings

SAILIFE Shareholdings

SAILIFE Promoter Holdings Trend

SAILIFE Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

SAILIFE Institutional Holdings Trend

SAILIFE Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

SAILIFE Shareholding Pattern

SAILIFE Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding34.50%29.56%2.76%19.91%13.26%

Dec 2025

Mar 2026

Jun 2026

Sep 2026

SAILIFE Shareholding History

SAILIFE Shareholding History

JunSepDec '25MarJunSep14.58%22.50%21.40%21.17%19.65%19.91%

Mutual Funds Invested in SAILIFE

Mutual Funds Invested in SAILIFE

No mutual funds holding trends are available

Top 5 Mutual Funds holding Sai Life Sciences Limited




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
3.0238%1.24%0.20%206/273 (0)
2.5064%5.14%0.24%1/81 (0)
1.9734%5.36%0.63%5/48 (+1)

Compare 3-month MF holding change on Screener

SAILIFE Insider Trades & Bulk Stock Deals

SAILIFE Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing SAILIFE stock

smallcases containing SAILIFE stock

Looks like this stock is not in any smallcase yet.

SAILIFE Events

SAILIFE Events

SAILIFE Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

SAILIFE Dividend Trend

No dividend trend available

SAILIFE Dividends

SAILIFE Dividends

Hmm, looks like data is unavailable here. Please come back after some time

SAILIFE Stock News & Opinions

SAILIFE Stock News & Opinions

Spotlight
Spotlight
Sai Life Sciences Ltd gains for fifth session

Sai Life Sciences Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 1549.8, up 3.62% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.72% on the day, quoting at 23102.8. The Sensex is at 74677.67, up 0.71%. Sai Life Sciences Ltd has risen around 0.56% in last one month. Meanwhile, Nifty Pharma index of which Sai Life Sciences Ltd is a constituent, has risen around 3.43% in last one month and is currently quoting at 26710.8, up 1.88% on the day. The volume in the stock stood at 7.68 lakh shares today, compared to the daily average of 4.37 lakh shares in last one month.The PE of the stock is 88.15 based on TTM earnings ending June 26.

3 days agoCapital Market - Live
Corporate
Corporate
Sai Life Sciences allotted shares under its 2008 plan, increasing equity capital

Sai Life Sciences Limited announced the allotment of 54,500 fully paid-up equity shares with a face value of Rs 1 each under its Employees Stock Option Plan 2008, increasing the company's issued, subscribed, and paid-up equity share capital from Rs 21,24,18,217 to Rs 21,24,72,716. The allotment was approved by the company's board of directors in a meeting held on October 12, 2026, and the exercise price per share was Rs 188.90.

2 weeks agoCapital Market - Live
Corporate
Corporate
Sai Life Sciences reported securities dematerialization details to Indian stock exchanges

Sai Life Sciences Limited informed the National Stock Exchange of India Limited and the BSE Limited that it has certified the details of securities dematerialized/rematerialized during the quarter ended September 30, 2026, as required under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, and furnished them to all stock exchanges where the company is listed, according to a filing on October 5, 2026. KFin Technologies Limited acted as the Registrar to an Issue and Share Transfer Agent for Sai Life Sciences Limited.

4 weeks agoCapital Market - Live
Corporate
Corporate
Sai Life Sciences to review financial results at board meeting on November 5, 2026

Sai Life Sciences Limited will hold a board meeting on Thursday, November 5, 2026, to consider and approve the standalone and consolidated unaudited financial results for the second quarter and half year ended September 30, 2026, as well as other corporate matters. The trading window for the company's securities was closed for designated persons and their immediate relatives from October 1, 2026, and will remain closed until November 7, 2026.

1 month agoCapital Market - Live
Corporate
Corporate
Sai Life Sciences halts securities trading ahead of Q2/H1 2026 results announcement

Sai Life Sciences Limited will close its trading window for securities from October 1, 2026, until 48 hours after the announcement of its unaudited financial results for the second quarter and half year ending September 30, 2026, in compliance with SEBI’s Prohibition of Insider Trading Regulations and the company’s Code of Conduct.

1 month agoCapital Market - Live
Spotlight
Spotlight
Sai Life Sciences Ltd up for third consecutive session

Sai Life Sciences Ltd is up for a third straight session today. The stock is quoting at Rs 1617, up 1.03% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.29% on the day, quoting at 23413.6. The Sensex is at 74818.76, up 0.71%. Sai Life Sciences Ltd has gained around 12.61% in last one month. Meanwhile, Nifty Pharma index of which Sai Life Sciences Ltd is a constituent, has gained around 2.67% in last one month and is currently quoting at 26710.1, up 1.25% on the day. The volume in the stock stood at 2.26 lakh shares today, compared to the daily average of 9.32 lakh shares in last one month.The PE of the stock is 94.34 based on TTM earnings ending June 26.

1 month agoCapital Market - Live
Corporate
Corporate
Sai Life Sciences allotted equity shares under its 2008 plan, increasing capital

Sai Life Sciences Limited announced the allotment of 24,000 fully paid-up equity shares with a face value of Rs 1 each under its Employees Stock Option Plan 2008, according to a regulatory filing on September 18, 2026. The allotment increased the company's issued, subscribed, and paid-up equity share capital from Rs 21,23,94,217 to Rs 21,24,18,216.

1 month agoCapital Market - Live
Corporate
Corporate
Sai Life Sciences allotted shares under two employee stock option plans, increasing equity capital

Sai Life Sciences Limited announced the allotment of 14,600 shares under the Employees Stock Option Plan 2008 and 66,000 shares under the Management Employee Stock Option Plan 2018, increasing the company’s issued, subscribed, and paid-up equity share capital from Rs 21,23,13,617 to Rs 21,23,94,216. The exercise price was Rs 188.90 per share for the ESOP 2008 allotment and Rs 23.30 per share for the MESOP 2018 allotment, with a premium of Rs 187.90 and Rs 22.30 respectively.

2 months agoCapital Market - Live
Spotlight
Spotlight
Sai Life Sciences Ltd soars 1.59%, up for third straight session

Sai Life Sciences Ltd rose for a third straight session today. The stock is quoting at Rs 1467.4, up 1.59% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.77% on the day, quoting at 24283.3. The Sensex is at 77581.77, down 0.73%. Sai Life Sciences Ltd has added around 15.35% in last one month. Meanwhile, Nifty Pharma index of which Sai Life Sciences Ltd is a constituent, has added around 3.88% in last one month and is currently quoting at 26750.45, down 0.42% on the day. The volume in the stock stood at 2.73 lakh shares today, compared to the daily average of 5.5 lakh shares in last one month.The PE of the stock is 85.03 based on TTM earnings ending June 26.

2 months agoCapital Market - Live
Spotlight
Spotlight
Sai Life Sciences Ltd gains for third consecutive session

Sai Life Sciences Ltd gained for a third straight session today. The stock is quoting at Rs 1383, up 1.21% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.37% on the day, quoting at 24523.85. The Sensex is at 78409.43, down 0.02%. Sai Life Sciences Ltd has risen around 12.2% in last one month. Meanwhile, Nifty Pharma index of which Sai Life Sciences Ltd is a constituent, has risen around 2.37% in last one month and is currently quoting at 26597.5, down 0.44% on the day. The volume in the stock stood at 1.7 lakh shares today, compared to the daily average of 3.72 lakh shares in last one month.The PE of the stock is 83.34 based on TTM earnings ending March 26.

2 months agoCapital Market - Live

Frequently asked questions

  1. The share price of SAILIFE as on 2nd November 2026 is ₹1542.30. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. The past returns of Sai Life Sciences Limited (SAILIFE) share are
    • Past 1 week: 11.43%
    • Past 1 month: 0.03%
    • Past 3 months: 17.66%
    • Past 6 months: 43.04%
    • Past 1 year: 67.69%
    • Past 3 years: N/A%
    • Past 5 years: 102.35%

  3. Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Sai Life Sciences Limited (SAILIFE) is ₹33092.63 Cr as of 2nd November 2026.

  4. The 52-week high of Sai Life Sciences Limited (SAILIFE) is ₹1697 and the 52-week low is ₹783.85.

  5. The P/E (price-to-earnings) ratio of Sai Life Sciences Limited (SAILIFE) is 94.85. The P/B (price-to-book) ratio is 13.32.

  6. Sai Life Sciences Limited (SAILIFE) belongs to the Health Care sector & Biotechnology sub-sector.

  7. You can directly buy Sai Life Sciences Limited (SAILIFE) shares on Tickertape. Simply sign up, connect your demat account and place your order.